profit from every $100 of sales.
$0$100
McKesson
$1,077.05-0.25% today
+28.1% in 1 year
1-year low $725.171-year high $1,082.59
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2021 to 2026.
0%20% a year
You pay $26.11 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What McKesson sold, what it kept, and what it did with the cash.
Sales went from $277 billion in 2023 to $403 billion in 2026, with $4.76 billion of profit last year.
SalesProfit
McKesson handed back 95% of the cash it generated last year.
Buybacks $4.8B
Free cash flow 2026$5.4B
Bought back its own shares$4.8B
Paid as dividends$381M
Cash vs. debt$4.0B vs. $8.6B
McKesson vs. similar companies
McKesson grows in the middle of these 5 and is priced in the middle for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| McKesson | 26.1× · Fair price | ||
 Cencora | 42.9× · Expensive | ||
 Cardinal Health | 41.2× · Expensive | ||
 Sigma Healthcare | 63.0× · Very expensive | ||
 Henry Schein | 23.9× · Fair price |
Compare McKesson with AbbVie · Bristol-Myers Squibb · Cardinal Health · Cencora · Johnson & Johnson · Eli Lilly · Medtronic · Merck &
AI analysis
An AI analyst reads McKesson's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| 238,228 | 263,966 | 276,711 | 308,951 | 359,051 | 403,430 | |
| 12,148 | 13,130 | 12,358 | 12,828 | 13,323 | 14,550 | |
| -5,040 | 2,038 | 4,582 | 4,171 | 4,816 | 6,454 | |
| -4,473 | 2,418 | 5,486 | 4,676 | 5,260 | 7,177 | |
| -4,539 | 1,114 | 3,560 | 3,002 | 3,295 | 4,762 | |
| -28.26 | 7.23 | 25.03 | 22.39 | 25.72 | 38.38 | |
| 5.1% | 5.0% | 4.5% | 4.2% | 3.7% | 3.6% | |
| -2.1% | 0.8% | 1.7% | 1.4% | 1.3% | 1.6% | |
| -1.9% | 0.4% | 1.3% | 1.0% | 0.9% | 1.2% |
Balance sheet
| In millions of USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Total assets | 65,015 | 63,298 | 62,320 | 67,443 | 75,140 | 82,323 |
| Cash | 6,278 | 3,532 | 4,678 | 4,583 | 5,691 | 3,975 |
| Total debt | 9,015 | 7,245 | 7,295 | 7,390 | 7,390 | 8,614 |
| Total liabilities | – | – | 63,810 | 69,042 | 76,834 | 83,157 |
| -21 | -2,272 | -1,857 | -1,971 | -2,074 | -2,172 | |
| 161 | 154 | 142 | 134 | 128 | 124 | |
| -42.3% | 33.5% | 70.9% | 58.9% | 68.7% | 79.1% | |
| 21,614.3% | -49.0% | -191.7% | -152.3% | -158.9% | -219.2% |
Cash flow
| In millions of USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| 4,542 | 4,434 | 5,159 | 4,314 | 6,085 | 6,155 | |
| 451 | 388 | 558 | 687 | 859 | 745 | |
| 4,091 | 4,046 | 4,601 | 3,627 | 5,226 | 5,410 | |
| Dividends paid | 276 | 277 | 292 | 314 | 345 | 381 |
| 742 | 3,516 | 3,638 | 3,025 | 3,146 | 4,750 | |
| 151 | 161 | 162 | 182 | 226 | 247 |
Valuation
- 26.1×
- 25.0×
- –
- -57.4×
- 0.3×
- 23.0×
- 18.0×
- 4.4%
- 3.8%
- 0.4%
Profitability
- 3.6%
- 1.6%
- 1.2%
- 1.8%
- 81.1%
- 71.1%
- -265.4%
- 5.8%
- 41.6%
- –
Growth
- +11.1%
- –
- +9.4%
- +13.0%
- −4.4%
Financial health
- 0.6×
- -3.97
- 10.5%
- 26.1×
- 0.85
- 0.49
- 4.90
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 1%of 956
Bottom 31%of 885
Top 48%of 575
Top 48%of 872
Top 26%of 986
What analysts expect
- Average price target
- $1,006.50
- Range
- $966.00 – $1,085.00
- 3 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | 11.69 | 11.56 | +1.1% |
| Feb 4, 2026 | 9.34 | 9.17 | +1.9% |
| Nov 5, 2025 | 9.86 | 9.03 | +9.2% |
| Aug 6, 2025 | 8.26 | 8.14 | +1.5% |
| May 8, 2025 | 10.12 | 9.83 | +3.0% |
| Feb 5, 2025 | 8.03 | 8.60 | −6.6% |
| Nov 6, 2024 | 7.07 | 6.88 | +2.8% |
| Aug 7, 2024 | 7.88 | 7.21 | +9.3% |
0.4%of the share price, paid each year
On $1,000 invested$4a year at today's yield, before tax
+13.0%2020 to 2025
Raised10 yearsin a row, in our data
Paid per share, each year
$1.04 in 2015 → $3.06 in 2025
How safe it looks
8.0% of its profit
Room to growStretchedMore than it earns: 7.0%
News
Is McKesson Stock Increasing Your Market Risk?Yahoo Finance · Nov 6, 2026Would You Have Held McKesson Stock All The Way Up?Yahoo Finance · Oct 21, 2026Why McKesson Stock Soared More Than 5% Higher TodayYahoo Finance · Oct 1, 20263 Reasons MCK Has Explosive Upside PotentialYahoo Finance · Sep 21, 2026McKesson Corporation (MCK) Is a Trending Stock: Facts to Know Before Betting on ItYahoo Finance · Sep 9, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
4/7Passes 4 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
71Pass
Benjamin Graham
53No pass
Philip Fisher
54No pass
Peter Lynch
41No pass
Joel Greenblatt
65Pass
Charlie Munger
60Pass
Terry Smith
64Pass
Questions about McKesson
Is McKesson a good stock to buy?
A business with weak numbers at a fair price. 4 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the McKesson AI analysis
What does McKesson do?
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. It is in Medical Distribution, based in Irving, TX, United States, with 41,600 employees.
Does McKesson pay a dividend?
Yes. At today's price the dividend is 0.4% a year, about 8% of its yearly profit. In 2026 it paid out $381 million in dividends.
Is McKesson stock halal?
Yes. McKesson passes our halal screen: its business is permitted and its debt is 7% of its market value, under the 30% limit. How we check
How has McKesson stock done over the past year?
Up 28.1% over the past twelve months, to $1,077.05. It traded between $725.17 and $1,082.59, close to its high.
Who are McKesson's competitors?
The largest listed companies in the same industry are Cencora, Cardinal Health, Sigma Healthcare and Henry Schein. The peers table on this page compares their profit, growth and price with McKesson's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.